hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells

Wen,Xiaoxia; Dong,Lei; Zhu,Jianjun; Chen,Yao

doi:10.3892/mmr.2013.1317

hcrcn81 is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells

Authors:
- Xiaoxia Wen
- Lei Dong
- Jianjun Zhu
- Yao Chen
View Affiliations

Affiliations: Department of Anatomy, Basic Medical and Forensic Medical Institute, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: February 8, 2013 https://doi.org/10.3892/mmr.2013.1317
Pages: 1257-1260

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to determine the role of hcrcn81 in the regulation of the mammalian target of rapamycin (mTOR) pathway in human colorectal adenocarcinoma cells. The effect of rapamycin treatment on hcrcn81 expression was evaluated by examining the mRNA and protein expression of hcrcn81 in rapamycin‑treated human colon carcinoma cell lines, SW480 and LoVo, using real‑time PCR and western blot analysis, respectively. The results demonstrated that mRNA and protein levels of hcrcn81 were elevated following rapamycin treatment in these cell lines, indicating that hcrcn81 expression is upregulated by rapamycin treatment in human colorectal adenocarcinoma cells. Observations of the current study indicate that hcrcn81 may play a role in tumorigenesis by regulating the mTOR signaling pathway.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Herrinton LJ, Liu L, Levin TR, Allison JE, Lewis JD and Velayos F: Incidence and mortality of colorectal adenocarcinoma in persons with inflammatory bowel disease from 1998 to 2010. Gastroenterology. 143:382–389. 2012. View Article : Google Scholar : PubMed/NCBI
3	Chen Y, Zhang Y, Zhou Z, Wang G and Yi Z: Identification of differentially expressed genes in human colorectal adenocarcinoma. World J Gastroenterol. 12:1025–1032. 2006.
4	Zhang C and Chen Y: Electronic cloning and validating of the suppression subtractive hybridization EST ES274070 of human colorectal adenocarcinoma. US Chin J Lymphol Oncol. 6:83–88. 2007.
5	Jiang Q, Zhang C and Chen Y: NM_001013649.3 gene is down-regulated in human colorectal adenocarcinoma. Mol Med Rep. 4:1279–1281. 2011.PubMed/NCBI
6	Zoncu R, Efeyan A and Sabatini DM: mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol. 12:21–35. 2011. View Article : Google Scholar : PubMed/NCBI
7	Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci. 122:3589–3594. 2009. View Article : Google Scholar : PubMed/NCBI
8	Feng Z, Zhang H, Levine AJ and Jin S: The coordinate regulation of the p53 and mTOR pathways in cells. Proc Natl Acad Sci USA. 102:8204–8209. 2005. View Article : Google Scholar : PubMed/NCBI
9	Gulhati P, Cai Q, Li J, et al: Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin Cancer Res. 15:7207–7216. 2009. View Article : Google Scholar : PubMed/NCBI
10	Chiang GG and Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 13:433–442. 2007. View Article : Google Scholar : PubMed/NCBI
11	Miyake N, Chikumi H, Takata M, Nakamoto M, Igishi T and Shimizu E: Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells. Oncol Rep. 28:848–854. 2012.PubMed/NCBI
12	Bustin SA, Benes V, Garson JA and Hellemans J: The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 55:611–622. 2009. View Article : Google Scholar : PubMed/NCBI
13	Roy HK, Olusola BF, Clemens DL, Karolski WJ, Ratashak A, Lynch HT and Smyrk TC: AKT proto-oncogene overexpression is an early event during sporadic colon carcinogenesis. Carcinogenesis. 23:201–205. 2002. View Article : Google Scholar : PubMed/NCBI
14	Johnson SM, Gulhati P, Rampy BA, et al: Novel expression patterns of PI3K/AKT/mTOR signaling pathway components in colorectal cancer. J Am Coll Surg. 210:767–778. 2010. View Article : Google Scholar : PubMed/NCBI
15	Vilar E, Mukherjee B, Kuick R, et al: Gene expression patterns in mismatch repair-deficient colorectal cancers highlight the potential therapeutic role of inhibitors of the phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway. Clin Cancer Res. 15:2829–2839. 2009.
16	Thimmaiah KN, Easton J, Huang S, Veverka KA, Germain GS, Harwood FC and Houghton PJ: Insulin-like growth factor I-mediated protection from rapamycin-induced apoptosis is independent of Ras-Erk1-Erk2 and phosphatidylinositol 30-kinase-Akt signaling pathways. Cancer Res. 63:364–374. 2003.PubMed/NCBI
17	Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M and Suthanthiran M: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res. 10:293–300. 2004. View Article : Google Scholar : PubMed/NCBI
18	Medici D and Olsen BR: Rapamycin inhibits proliferation of hemangioma endothelial cells by reducing HIF-1-dependent expression of VEGF. PLoS One. 7:e429132012. View Article : Google Scholar : PubMed/NCBI
19	Samkari A, Cooper ZA, Holloway MP, Liu J and Altura RA: Rapamycin induces the anti-apoptotic protein survivin in neuroblastoma. Int J Biochem Mol Biol. 3:28–35. 2012.PubMed/NCBI
20	Sun J and Jin T: Both Wnt and mTOR signaling pathways are involved in insulin-stimulated proto-oncogene expression in intestinal cells. Cell Signal. 20:219–229. 2008. View Article : Google Scholar : PubMed/NCBI